Savitz Ryan bought DNTH
March 31, 2026 · Form 4 insider transaction
Savitz Ryan bought 40,000 shares of Dianthus Therapeutics, Inc. at $17.88 per share, a transaction worth $715.2K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Acquired (buy-side)
Shares
40,000
Price
$17.88
Total value
$715.2K
InsiderSavitz Ryan
RoleOfficer
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMarch 31, 2026
Filing dateApril 1, 2026
Shares owned after114,367
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.